Case Study 1: AstraZeneca Fighting a Global Pandemic AstraZeneca is a global bio-pharmaceutical company headquartered in Cambridge, England, with revenues of $26.6 billion (2020). CHALLENGE: From Lab to Jab at Light Speed As COVID-19 spread throughout the world in the spring of 2020, AstraZeneca recognized the need for an effective COVID-19 vaccine to defeat the virus. In April 2020 AstraZeneca joined forces with the University of Oxford to make a meaningful difference and save lives. This landmark partnership brought together world-class expertise in vaccinology with AstraZeneca’s ability to deliver a global solution at scale. AstraZeneca’s research partners at Oxford University had demonstrated an immune response in preclinical studies and some encouraging early clinical results that provided a basis for confidence that a vaccine could be rapidly developed. AstraZeneca’s proven manufacturing capability and global supply chain would enable rapid progress from the research lab to developing a highly effective vaccine with a favorable safety profile that could be administered worldwide. AstraZeneca and Oxford University pledged to provide the vaccine on a not-for-profit basis. This commitment to broad and equitable access ensured that the vaccine would be available at cost during the pandemic and accessible to low-income countries after the pandemic subsided. To be successful, however, AstraZeneca would have to make every dollar count. Question Who are the 2 primary stakeholders?
AstraZeneca is a global bio-pharmaceutical company headquartered in Cambridge, England, with revenues of $26.6 billion (2020).
CHALLENGE: From Lab to Jab at Light Speed
As COVID-19 spread throughout the world in the spring of 2020, AstraZeneca recognized the need for an effective COVID-19 vaccine to defeat the virus. In April 2020 AstraZeneca joined forces with the University of Oxford to make a meaningful difference and save lives. This landmark partnership brought together world-class expertise in vaccinology with AstraZeneca’s ability to deliver a global solution at scale. AstraZeneca’s research partners at Oxford University had demonstrated an immune response in preclinical studies and some encouraging early clinical results that provided a basis for confidence that a vaccine could be rapidly developed.
AstraZeneca’s proven manufacturing capability and global supply chain would enable rapid progress from the research lab to developing a highly effective vaccine with a favorable safety profile that could be administered worldwide. AstraZeneca and Oxford University pledged to provide the vaccine on a not-for-profit basis. This commitment to broad and equitable access ensured that the vaccine would be available at cost during the pandemic and accessible to low-income countries after the pandemic subsided. To be successful, however, AstraZeneca would have to make every dollar count.
Question
Who are the 2 primary stakeholders?
Trending now
This is a popular solution!
Step by step
Solved in 3 steps
